Last reviewed · How we verify
Ferric Carboxymaltose Injection
Ferric Carboxymaltose Injection is a Iron replacement agent Small molecule drug developed by Sichuan Huiyu Pharmaceutical Co., Ltd. It is currently FDA-approved for Iron deficiency anemia in adults, Iron deficiency anemia in patients with chronic kidney disease, Iron deficiency anemia in patients intolerant to or with inadequate response to oral iron. Also known as: Ferinject, i.v. iron.
Ferric carboxymaltose delivers iron as a stable complex that is taken up by iron-binding proteins to replenish depleted iron stores and restore hemoglobin synthesis.
Ferric carboxymaltose delivers iron as a stable complex that is taken up by iron-binding proteins to replenish depleted iron stores and restore hemoglobin synthesis. Used for Iron deficiency anemia in adults, Iron deficiency anemia in patients with chronic kidney disease, Iron deficiency anemia in patients intolerant to or with inadequate response to oral iron.
At a glance
| Generic name | Ferric Carboxymaltose Injection |
|---|---|
| Also known as | Ferinject, i.v. iron |
| Sponsor | Sichuan Huiyu Pharmaceutical Co., Ltd |
| Drug class | Iron replacement agent |
| Target | Iron metabolism pathway; transferrin receptor |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Ferric carboxymaltose is an iron replacement therapy consisting of ferric iron complexed with carboxymaltose, a carbohydrate polymer. The complex protects iron from premature release while allowing controlled uptake by transferrin and other iron-binding proteins in the body. This restores iron stores in patients with iron deficiency and enables the bone marrow to produce adequate hemoglobin and red blood cells.
Approved indications
- Iron deficiency anemia in adults
- Iron deficiency anemia in patients with chronic kidney disease
- Iron deficiency anemia in patients intolerant to or with inadequate response to oral iron
Common side effects
- Injection site reactions
- Nausea
- Headache
- Dizziness
- Hypophosphatemia
- Abdominal pain
Key clinical trials
- Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome (PHASE4)
- Comparison of the Mean Change in Hemoglobin With Ferric Carboxymaltose and IV Iron Sucrose in Anemic Antenatal Patients (NA)
- Efficacy of Ferric Carboxymaltose Versus Iron Sucrose in Non-dialysis Dependent Chronic Kidney Disease Patients (NA)
- Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants (PHASE1)
- Effects of IV Iron Replacement on Exercise Capacity in Individuals With Heart Failure (PHASE4)
- Effect of Ultra-short-term Treatment of Patients With Iron Deficiency or Anemia Undergoing Adolescent Scoliosis Correction (NA)
- Ferric Carboxymaltose Versus Iron Sucrose for Treating Anemia in Pregnant Women (PHASE4)
- The Role of Intravenous Ferritin in Optimizing Postoperative Recovery Following Pancreaticoduodenectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ferric Carboxymaltose Injection CI brief — competitive landscape report
- Ferric Carboxymaltose Injection updates RSS · CI watch RSS
- Sichuan Huiyu Pharmaceutical Co., Ltd portfolio CI
Frequently asked questions about Ferric Carboxymaltose Injection
What is Ferric Carboxymaltose Injection?
How does Ferric Carboxymaltose Injection work?
What is Ferric Carboxymaltose Injection used for?
Who makes Ferric Carboxymaltose Injection?
Is Ferric Carboxymaltose Injection also known as anything else?
What drug class is Ferric Carboxymaltose Injection in?
What development phase is Ferric Carboxymaltose Injection in?
What are the side effects of Ferric Carboxymaltose Injection?
What does Ferric Carboxymaltose Injection target?
Related
- Drug class: All Iron replacement agent drugs
- Target: All drugs targeting Iron metabolism pathway; transferrin receptor
- Manufacturer: Sichuan Huiyu Pharmaceutical Co., Ltd — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Iron deficiency anemia in adults
- Indication: Drugs for Iron deficiency anemia in patients with chronic kidney disease
- Indication: Drugs for Iron deficiency anemia in patients intolerant to or with inadequate response to oral iron
- Also known as: Ferinject, i.v. iron
- Compare: Ferric Carboxymaltose Injection vs similar drugs
- Pricing: Ferric Carboxymaltose Injection cost, discount & access